HighGravityData
Companies / Biopharma / AMGN

Amgen

AMGN · Biopharma sector group
Guidance from Amgen’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Current guidance
11 items
Releases tracked
8
Latest release
Aug 4, 2026
Data checked
Aug 4, 2026
On this page:Latest changes·Current guidance·Your sector group·History

What changed in the Aug 4, 2026 release

Each item compared with the same item in the previous release (Apr 30, 2026). Values in quotation marks are the company’s words.

New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
ChangeMetricPeriodPreviousNowSource
RaisedTotal revenuesfor FY2026“$37.1 billion to $38.5 billion”“$38.2 billion to $39.4 billion”Filing ↗
RaisedEPS (GAAP basis)for FY2026“$15.45 to $16.94”“$15.80 to $17.08”Filing ↗
RaisedEPS (non-GAAP basis)for FY2026“$21.60 to $23.00”“$22.30 to $23.50”Filing ↗
LoweredTax rate (GAAP basis)for FY2026“15.5% to 17.0%”“14.5% to 16.0%”Filing ↗
LoweredTax rate (non-GAAP basis)for FY2026“16.0% to 17.5%”“15.0% to 16.5%”Filing ↗
ReiteratedCapital expendituresfor FY2026“approximately $2.6 billion”“approximately $2.6 billion”Filing ↗
Show 3 items not restated in this release
ChangeMetricPeriodPreviousNowSource
Not restatedGAAP diluted EPSfor FY2026“$ 15.62 — $ 17.10”—Filing ↗
Not restatedNon-GAAP diluted EPSfor FY2026“$ 21.70 — $ 23.10”—Filing ↗
Not restatedNet selling pricefor FY2026“decline by roughly mid single-digits”—Filing ↗

Current guidance

Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.

Current fiscal year
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Total revenues“$38.2 billion to $39.4 billion”for FY2026GAAP-tiedFeb 3, 20263Filing ↗
EPS (GAAP basis)“$15.80 to $17.08”for FY2026GAAP-tiedFeb 3, 20262Filing ↗
EPS (non-GAAP basis)“$22.30 to $23.50”for FY2026Company-definedFeb 3, 20262Filing ↗
GAAP diluted EPS“$ 15.62 — $ 17.10”for FY2026GAAP-tiedApr 30, 20261Filing ↗
Non-GAAP diluted EPS“$ 21.70 — $ 23.10”for FY2026Company-definedApr 30, 20261Filing ↗
Capital expenditures“approximately $2.6 billion”for FY2026Company-definedFeb 3, 20263Filing ↗
GAAP tax rate“14.5 % — 16.0 %”for FY2026Company-definedApr 30, 20261Filing ↗
Net selling price“decline by roughly mid single-digits”for FY2026Company-definedFeb 3, 20261Filing ↗
Non-GAAP tax rate“15.0 % — 16.5 %”for FY2026Company-definedApr 30, 20261Filing ↗
Share repurchases“not to exceed $3.0 billion”for FY2026Declared actionFeb 3, 20263Filing ↗
Tax rate (GAAP basis)“14.5% to 16.0%”for FY2026Company-definedFeb 3, 20262Filing ↗
Tax rate (non-GAAP basis)“15.0% to 16.5%”for FY2026Company-definedFeb 3, 20262Filing ↗

How one item moved

Total revenues, for FY2026 — every statement across the year, each linked to its filing.

Feb 3, 2026
New
“$37.0 billion to $38.4 billion”
Filing ↗
Apr 30, 2026
Raised
“$37.1 billion to $38.5 billion”
Filing ↗
Aug 4, 2026
Raised
“$38.2 billion to $39.4 billion”
Filing ↗

How your Biopharma sector group guides

12 companies in Biopharma. What they guide on, and who reported this season.

Most-guided metric families
Revenue
11
Adjusted EPS
6
GAAP EPS
5
Tax rate
5
Buybacks
5
Gross margin
4
Capex
3
Dividends
3
This season’s releases
BioMarin PharmaceuticalAug 6, 202619 changes
Halozyme TherapeuticsAug 6, 20266 changes
Eli LillyAug 5, 20265 changes
AmgenAug 4, 20265 changes
Gilead SciencesAug 4, 202615 changes
ModernaJul 31, 20268 changes
Neurocrine BiosciencesJul 30, 202616 changes
Regeneron PharmaceuticalsJul 30, 202622 changes
Get this for your own peer set — Peer Guidance Briefing, $3,000.

Full history

Every metric, every release, eight quarters — the complete record as one table.

MetricFY2026FY2025FY2024
Total revenues3 statements4 statements1 statement
EPS (GAAP basis)2 statements3 statements1 statement
EPS (non-GAAP basis)2 statements3 statements1 statement
GAAP diluted EPS1 statement1 statement—
Non-GAAP diluted EPS1 statement1 statement—
The full record for Amgen and its Biopharma peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.

Filings

The 8 earnings releases this page is built from.

FiledFiscal periodAccessionGuidance items
Aug 4, 2026FY2026 Q20000318154-26-0001247Open filing ↗
Apr 30, 2026FY2026 Q10000318154-26-0000547Open filing ↗
Feb 3, 2026FY2025 Q40000318154-26-0000038Open filing ↗
Nov 4, 2025FY2025 Q30000318154-25-0000708Open filing ↗
Aug 5, 2025FY2025 Q20000318154-25-0000548Open filing ↗
May 1, 2025FY2025 Q10000318154-25-0000188Open filing ↗
Feb 4, 2025FY2024 Q40000318154-25-0000058Open filing ↗
Oct 30, 2024FY2024 Q30000318154-24-0000428Open filing ↗
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error